Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 23, Pages 9776-9795Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm5012808
Keywords
-
Categories
Funding
- Cystic Fibrosis Foundation Therapeutics
Ask authors/readers for more resources
Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available